Raiffeisen Bank International’s Editas Medicine EDIT Stock Holding History

Raiffeisen Bank International’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$27.9K	–	844
2025 Q2	$22K	Hold	10,000	–	–	﹤0.01%	524
2025 Q1	$11.6K	Hold	10,000	–	–	﹤0.01%	553
2024 Q4	$12K	Buy	+10,000	New	+$25.5K	﹤0.01%	555

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raiffeisen Bank International's EDIT Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Editas Medicine (EDIT) in Q3 2025, closing a stake of 10,000 shares — an estimated $27.9K sold.

Raiffeisen Bank International first reported a position in EDIT in Q4 2024 and held it in 3 quarters. The position peaked at $22K in Q2 2025. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

Raiffeisen Bank International reported no remaining Editas Medicine position as of Q3 2025 after selling out during the quarter.
Raiffeisen Bank International sold 10,000 Editas Medicine shares in Q3 2025, an estimated $27.9K.
Raiffeisen Bank International first reported a position in Editas Medicine in Q4 2024 and held it in 3 quarters.
Raiffeisen Bank International's Editas Medicine position peaked at $22K in Q2 2025.
193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.